INmune Bio, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.016 million. Net loss was USD 6.84 million compared to USD 6.66 million a year ago. Basic loss per share from continuing operations was USD 0.38 compared to USD 0.44 a year ago.
For the six months, sales was USD 0.179 million compared to USD 0.004 million a year ago. Net loss was USD 13.74 million compared to USD 11.21 million a year ago. Basic loss per share from continuing operations was USD 0.77 compared to USD 0.77 a year ago.